Scarica l'app Stockscreener
23.54
6.95%
1.53
Dopo l'orario di chiusura:
23.54
Precedente Chiudi:
$22.01
Aprire:
$21.41
Volume 24 ore:
2.48M
Relative Volume:
2.88
Capitalizzazione di mercato:
$1.40B
Reddito:
-
Utile/perdita netta:
$-131.11M
Rapporto P/E:
-10.83
EPS:
-2.1745
Flusso di cassa netto:
$-102.47M
1 W Prestazione:
-5.31%
1M Prestazione:
-10.32%
6M Prestazione:
-32.24%
1 anno Prestazione:
+97.65%
Intervallo 1D:
$21.27
$23.64
Intervallo di 1 settimana:
$18.66
$29.56
Portata 52W:
$11.70
$40.65
Tyra Biosciences Inc Stock (TYRA) Company Profile
Nome
Tyra Biosciences Inc
Settore
Industria
Telefono
(619) 728-4760
Indirizzo
2656 STATE STREET, CARLSBAD
Compare TYRA vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TYRA
Tyra Biosciences Inc
|
23.54 | 1.31B | 0 | -131.11M | -102.47M | -2.1745 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-15 | Iniziato | Guggenheim | Buy |
| 2026-04-06 | Iniziato | Canaccord Genuity | Buy |
| 2026-02-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2026-02-10 | Iniziato | William Blair | Outperform |
| 2026-01-28 | Iniziato | Barclays | Overweight |
| 2025-09-03 | Iniziato | Raymond James | Strong Buy |
| 2025-05-21 | Ripresa | Piper Sandler | Overweight |
| 2025-01-07 | Iniziato | UBS | Buy |
| 2024-10-18 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-08-15 | Iniziato | Piper Sandler | Overweight |
| 2023-12-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-06-30 | Iniziato | Wedbush | Outperform |
| 2023-02-03 | Iniziato | Oppenheimer | Outperform |
| 2022-06-23 | Iniziato | H.C. Wainwright | Buy |
| 2022-03-08 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-11-08 | Downgrade | Jefferies | Buy → Hold |
| 2021-10-11 | Iniziato | BofA Securities | Buy |
| 2021-10-11 | Iniziato | Cowen | Outperform |
| 2021-10-11 | Iniziato | Jefferies | Buy |
Mostra tutto
Tyra Biosciences Inc Borsa (TYRA) Ultime notizie
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc.TYRA - PR Newswire
Tyra Biosciences Inc. (TYRA) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
A Quick Look at Today's Ratings for TYRA BIOSCIENCES, INC.(TYRA.US), With a Forecast Between $30 to $59 - Moomoo
Dabogratinib Shows Early Activity in FGFR3-Altered Low-Grade NMIBC - CancerNetwork
Cantor Fitzgerald reiterates Tyra Biosciences stock rating after trial data - Investing.com
Tyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBCSlideshow (NASDAQ:TYRA) 2026-09-10 - Seeking Alpha
Tyra Biosciences at 12th Annual Cantor Fitzgerald Global Healthcare Conference: oral drug push - Investing.com Canada
Balversa reversa? Tyra’s bladder cancer drug hits in phase II - BioWorld News
Tyra disappoints investors with bladder cancer data - BioPharma Dive
Why This Biotech Stock Just Plummeted To A 10-Month Low - Investor's Business Daily
TYRA: Oral FGFR3 inhibitor shows robust efficacy and safety, advancing to phase III for MIBC - TradingView
Tyra Biosciences Tanks As IR NMIBC Data Disappoints: I'm Firmly On The Sidelines (TYRA) - Seeking Alpha
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Why Is Tyra Biosciences Stock Sinking Wednesday? - Benzinga
Tyra Biosciences reports 79% response rate for bladder cancer drug dabogratinib - Minichart
Tyra Biosciences (TYRA) Shares Plunge 22% as Bladder Cancer Drug Trial Falls Short - Blockonomi
TYRA: Oral dabogratinib at 60 mg shows strong efficacy and safety, advancing to phase III in NMIBC - TradingView
Tyra reports 79% response rate in Phase 2 cancer trial - grafa.com
Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress - Barron's
Tyra Biosciences stock tumbles 30% on phase 2 trial results By Investing.com - Investing.com Australia
Tyra Biosciences shares plunge 30% after Phase 2 dabogratinib data - finance.yahoo.com
Why is Tyra Biosciences stock plunging today? - Investing.com
Tyra drops after mid-stage trial data for lead asset in bladder cancer - TradingView
Tyra Bioscience Reports Promising Phase 2 Dabogratinib Data - TipRanks
Tyra Biosciences reports positive Phase 2 SURF302 results, 60 mg QD chosen for registrational adjuvant plan - TradingView
Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib - PR Newswire
We're Hopeful That Tyra Biosciences (NASDAQ:TYRA) Will Use Its Cash Wisely - Moomoo
Tyra Biosciences to present at Cantor Global He... - Pluang
Tyra Biosciences sets virtual chat, investor meetings Sept. 9 - Stock Titan
A Quick Look at Today's Ratings for TYRA BIOSCIENCES, INC.(TYRA.US), With a Forecast Between $39 to $56 - Moomoo
Piper Sandler reiterates Tyra Biosciences stock rating ahead of data By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Tyra Biosciences stock rating at buy By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Tyra Biosciences stock rating at buy - Investing.com
Piper Sandler Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $56 - Moomoo
BofA Securities Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $39 - Moomoo
JonesTrading Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $56 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Tyra Biosciences downgraded to Hold ahead of ke... - Pluang
Tyra Biosciences: 'Hold' IR-NMIBC Data September 9th 2026, With Caution Ahead For 2027 Readouts - Seeking Alpha
TYRA Stock Heads For Best Day In Nearly 10 Months — Sets Date For Key Phase 2 Bladder Cancer Drug Readout - Asianet Newsable
Tyra Bio rises on upcoming mid-stage trial data (TYRA:NASDAQ) - Seeking Alpha
Initial results for an oral bladder cancer drug will be discussed Sept. 9 - Stock Titan
How Tyra Biosciences Inc. (TYRA) Affects Rotational Strategy Timing - Stock Traders Daily
Tyra Biosciences draws industry focus with IR NMIBC research at IBCG26 retreat - Traders Union
Tyra Biosciences (TYRA): Can Dabogratinib Redefine FGFR3-Driven Bladder Cancer? - RTTNews
Tyra Biosciences Inc (TYRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CCORF Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Tyra (TYRA) Results Check: EPS Falls Short of Its Estimate in the Current Update; Post-Earnings: The Market Price Moves 0.65% Higher in the Latest ReadingFinancial Data - vinanet.vn
Tyra’s one-drug, three-indication bet nears its first phase 2 test - Pharma Voice
Farallon Capital Management Slashes Tyra Biosciences (TYRA) Stak - GuruFocus
Tyra Biosciences Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Tyra Biosciences Inc Azioni (TYRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):